IBRX270115P00005000
IBRX Jan 15 2027 5.00 Put
optionOPRA
EODOct 15, 2026
0.29USD+3.571%(+0.01)172Vol4,922OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
5
Expiration
Jan 15, 2027
DTE
87d
Moneyness
OTM
Intrinsic
$0.00
IBRX 5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $0.10 | +0.00% | 1 | 256 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.29 | +3.57% | 172 | 4,922 |
| Mar 19, 2027 | 150d | $0.35 | +0.00% | 8 | 130 |
| Apr 16, 2027 | 178d | $0.45 | -31.82% | 2 | 3 |
| May 21, 2027 | 213d | $0.53 | -3.64% | 2 | 15 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | $1.50 | +3.45% | 5 | 40 |
| Jan 21, 2028 | 458d | $0.98 | +8.89% | 1 | 974 |
| Mar 17, 2028 | 514d | $1.50 | -7.98% | 20 | 26 |
| Jan 19, 2029 | 822d | — | — | 0 | 0 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 P | $0.03 | -40.00% | 72 | 2,010 | OTM |
| 2.5 P | $0.05 | +0.00% | 1 | 8,454 | OTM |
| 3 P | $0.05 | -50.00% | 18 | 2,647 | OTM |
| 3.5 P | $0.12 | +20.00% | 2 | 1,305 | OTM |
| 4 P | $0.20 | +0.00% | 80 | 272 | OTM |
| 4.5 P | $0.20 | +25.00% | 20 | 439 | OTM |
| 5 P | $0.29 | +3.57% | 172 | 4,922 | OTM |
| 5.5 P | $0.30 | -14.29% | 30 | 33,349 | OTM |
| 7.5 P | $0.90 | +20.00% | 121 | 22,697 | OTM |
| 9 P | $1.62 | +5.88% | 72 | 52,470 | ITM |
| 10 P | $2.06 | +1.48% | 50 | 6,506 | ITM |
| 11 P | $2.65 | -7.02% | 7 | 150 | ITM |
| 12 P | $3.30 | -10.81% | 4 | 881 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.